PROTAC-mediated degradation of Bruton's tyrosine kinase is inhibited by covalent binding

Christopher P. Tinworth, Hannah Lithgow, Lars Dittus, Zuni I. Bassi, Sophie E. Hughes, Marcel Muelbaier, Han Dai, Ian E. D. Smith, William J. Kerr, Glenn A. Burley, Marcus Bantscheff, John D. Harling

Research output: Contribution to journalArticle

32 Citations (Scopus)
11 Downloads (Pure)

Abstract

The impact of covalent binding on PROTAC-Mediated degradation of BTK was investigated through the preparation of both covalent binding and reversible binding PROTACs derived from the covalent BTK inhibitor ibrutinib. It was determined that a covalent binding PROTAC inhibited BTK degradation despite evidence of target engagement, while BTK degradation was observed with a reversible binding PROTAC. These observations were consistently found when PROTACs that were able to recruit either IAP or cereblon E3 ligases were employed. Proteomics analysis determined that the use of a covalently bound PROTAC did not result in the degradation of covalently bound targets, while degradation was observed for some reversibly bound targets. This observation highlights the importance of catalysis for successful PROTAC-Mediated degradation and highlights a potential caveat for the use of covalent target binders in PROTAC design.

Original languageEnglish
Pages (from-to)342-347
Number of pages6
JournalACS Chemical Biology
Volume14
Issue number3
Early online date26 Feb 2019
DOIs
Publication statusPublished - 15 Mar 2019

Keywords

  • PROTAC
  • drug discovery
  • cellular degradation
  • protein degradation
  • E3 ubiquitin-protein ligases
  • tyrosine kinase

Fingerprint Dive into the research topics of 'PROTAC-mediated degradation of Bruton's tyrosine kinase is inhibited by covalent binding'. Together they form a unique fingerprint.

Cite this